Investigation of the effect of solubility increase at the main absorption site on bioavailability of BCS class II drug (risperidone) using liquisolid technique.
BCS class II drugs usually suffer inadequate bioavailability as dissolution step is the absorption rate limiting step. In this work, the effect of solubility increase at the main absorption site for these drugs was investigated using risperidone as a drug model. Liquisolid technique was applied to prepare risperidone per-oral tablets of high dissolution rate at intestinal pH (6.8) using versatile nonionic surfactants of high solubilizing ability [Transcutol HP, Labrasol and Labrasol/Labrafil (1:1) mixture] as liquid vehicles at different drug concentrations (10-30%) and fixed (R). The prepared liquisolid tablets were fully evaluated and the dissolution rate at pH 6.8 was investigated. The formulae that showed significantly different release rate were selected and subjected to mathematical modeling using DE25, MDT and similarity factor (f2). Depending on mathematical modeling results, formula of higher dissolution rate was subjected to solid state characterization using differential scanning calorimetric (DSC), infrared spectroscopy (IR) and X-ray diffraction (XRD). Finally, the drug bioavailability was studied in comparison to conventional tablets in rabbits. Results showed that liquisolid tablet prepared using Labrasol/Labrafil (1:1) mixture as liquid vehicle containing 10% risperidone is a compatible formula with law drug crystallinity and higher dissolution rate (100% in 25 min). The drug bioavailability was significantly increased in comparison to the conventional tablets (1441.711 μg h/mL and 137.518 μg/mL in comparison to 321.011 μg h/mL and 38.673 μg/mL for AUC and Cpmax, respectively). This led to the conclusion that liquisolid technique was efficiently improved drug solubility and solubility increase of BCS class II drugs at their main absorption site significantly increases their bioavailability.
a Department of Pharmaceutics and Industrial Pharmacy , Beni-suef University , Beni-suef , Egypt and.|b Department of Pharmaceutics and Pharmacy Technology , Taif University , Taif , Saudi Arabia.
Ahmed
A
Khames
D000818:Animals; D001682:Biological Availability; D002220:Carbamazepine / Q000138:chemical synthesis / Q000378:metabolism / Q000494:pharmacology; D002626:Chemistry, Pharmaceutical / Q000379:methods*; D018592:Cross-Over Studies; D004337:Drug Carriers / Q000138:chemical synthesis / Q000378:metabolism* / Q000494:pharmacology; D007408:Intestinal Absorption / Q000187:drug effects / Q000502:physiology*; D008297:Male; D008962:Models, Theoretical; D011817:Rabbits; D011897:Random Allocation; D018967:Risperidone / Q000138:chemical synthesis / Q000378:metabolism* / Q000494:pharmacology; D012995:Solubility; D014961:X-Ray Diffraction
D004337:Drug Carriers; D002220:Carbamazepine; D018967:Risperidone
BCS class II drugs; Liquisolid; bioavailability; labrasol/labrafil mixture; risperidone